Ell C, Schoerner C, Solbach W, Stolte M, Vieth M, Ridl W, Moser W
Department of Internal Medicine II, HSK Wiesbaden, Germany.
Eur J Gastroenterol Hepatol. 2001 Jun;13(6):685-91. doi: 10.1097/00042737-200106000-00012.
Besides antibiotics, additionally effective acid inhibition is necessary for the eradication of Helicobacter pylori.
To assess the significance of acid suppression and, in particular, treatment with proton pump inhibitors (PPIs) compared with H2 receptor antagonists (H2 RAs). The primary target parameter for the study was H. pylori eradication. In addition, the ulcer healing rate, speed of pain reduction, score for gastritis in the antrum and gastric body, and rate of side effects were recorded.
Randomized, double-blinded, multicentre study.
A total of 456 patients between the ages of 18 and 80 years with H. pylori-positive duodenal ulcers were included in the study.
Using a randomization list, patients were assigned either to a treatment group receiving omeprazole 40 mg once daily, amoxycillin 750 mg three times a day, and metronidazole 500 mg three times a day (OAM), or to a group receiving ranitidine 300 mg once daily, amoxycillin 750 mg three times a day, and metronidazole 500 mg three times a day (RAM). The treatment period was 7 days in both groups. Long-term acid-suppressant treatment was not given.
The eradication rate was 87.1% (169/194, intention to treat [ITT]) in the OAM group and 77% (137/ 178, ITT) in the RAM group. The difference of 10.1% (95% CI 2.5-18%) is statistically significant (P= 0.0104). The ulcer healing rate was 93.3% in the OAM group (181/194, ITT) and 92.1% in the RAM group (164/178, ITT, NS). With regard to the speed and intensity of pain reduction, the OAM group was superior to the RAM group. In patients in whom H. pylori eradication was successful, the reduction in the antral and gastric body gastritis score was significantly greater than in patients without eradication. In the OAM group, 39.1% of the patients (n = 90) reported one or more side effects, compared with 44.7% (n = 101) in the RAM group (P= 1.5449, NS).
Omeprazole (40 mg once daily in the morning) is significantly more effective than ranitidine (300 mg once daily in the morning) with respect to H. pylori eradication when used together with amoxycillin (750 mg three times a day) and metronidazole (500 mg three times a day) for a 7-day treatment period.
除抗生素外,有效抑制胃酸对于根除幽门螺杆菌也是必要的。
评估抑酸的重要性,尤其是比较质子泵抑制剂(PPI)与H2受体拮抗剂(H2RA)的治疗效果。本研究的主要目标参数是幽门螺杆菌根除率。此外,还记录了溃疡愈合率、疼痛缓解速度、胃窦和胃体胃炎评分以及副作用发生率。
随机、双盲、多中心研究。
共有456例年龄在18至80岁之间的幽门螺杆菌阳性十二指肠溃疡患者纳入本研究。
使用随机分组列表,将患者分为治疗组,一组接受奥美拉唑40mg每日一次、阿莫西林750mg每日三次和甲硝唑500mg每日三次(OAM),另一组接受雷尼替丁300mg每日一次、阿莫西林750mg每日三次和甲硝唑500mg每日三次(RAM)。两组治疗期均为7天,未给予长期抑酸治疗。
OAM组的根除率为87.1%(169/194,意向性分析[ITT]),RAM组为77%(137/178,ITT)。10.1%的差异(95%CI 2.5 - 18%)具有统计学意义(P = 0.0104)。OAM组的溃疡愈合率为93.3%(181/194,ITT),RAM组为92.1%(164/178,ITT,无统计学差异)。在疼痛缓解速度和强度方面,OAM组优于RAM组。幽门螺杆菌根除成功的患者,胃窦和胃体胃炎评分的降低显著大于未根除的患者。OAM组39.1%的患者(n = 90)报告有一项或多项副作用,RAM组为44.7%(n = 101)(P = 1.5449,无统计学差异)。
在联合阿莫西林(750mg每日三次)和甲硝唑(500mg每日三次)进行为期7天的治疗时,奥美拉唑(晨起每日一次40mg)在根除幽门螺杆菌方面比雷尼替丁(晨起每日一次300mg)显著更有效。